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Patients with relapsed and refractory Hodgkin lymphoma (HL) may experience long-term survival after
allogeneic stem cell transplantation (alloSCT), but disease recurrence represents the main cause of treatment
failure. Positron-emission tomography (PET)epositive patients after alloSCT have a dismal outcome. Serum
thymus and activation-regulated chemokine (TARC) is produced by Reed-Sternberg cells and may be a marker
of disease. Our study aimed at assessing whether TARC levels after alloSCT correlated with disease status and
whether TARC monitoring could increase the ability to predict relapse. Twenty-four patients were evaluated
in a prospective observational study. TARC serum level and PET were assessed before and after alloSCT during
the follow-up (median, 30 months; range, 2 to 54). Before alloSCT, the median TARC level was 721 pg/mL
(range, 209 to 1332) in PET-negative patients and 2542 pg/mL (range, 94 to 13,870) in PET-positive patients.
After alloSCT, TARC was 620 pg/mL (range, 12 to 4333) in persistently PET-negative patients compared with
22,397 pg/mL (range, 602 to 106,578) in PET-positive patients (P < .0001). In 7 patients who relapsed after
alloSCT, TARC level increased progressively even before PET became positive, with a median fold increase of
3.19 (range, 1.66 to 7.11) at relapse. The cut-off value of 1726 pg/mL had a sensitivity of 100% and a speciﬁcity
of 71% for PET positivity. Patients with at least 1 TARC value above 1726 pg/mL during the ﬁrst year after
alloSCT had a worse progression-free survival (P ¼ .031). In conclusion, TARC was correlated with disease
status and its monitoring may be able to predict PET positivity after alloSCT, thus potentially allowing an early
immune manipulation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION Positron-emission tomography (PET) scans have become
Patients affected by Hodgkin lymphoma (HL) who are
refractory or relapsed after an autologous transplantation
have a very poor prognosis and short-lasting responses after
chemotherapy [1,2]. Allogeneic stem cell transplantation
(alloSCT) with reduced-intensity conditioning may represent
a feasible option, but only 20% to 30% of allografted patients
experience long-term survival; disease recurrence remains
the main cause of treatment failure [3-7].edgments on page 1987.
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ty for Blood and Marrow Transplantation.the ﬁrst-choice exam for staging and response evaluation in
HL patients. In the setting of alloSCT, PET has shown to be the
most sensitive exam to detect lymphoma relapse [8-10].
Patients who are or become PET-positive after an alloSCT
have a very dismal outcome because of the unavailability of
curative treatment options [11]. The real beneﬁt of donor
lymphocyte infusions is still unclear, as most of the responses
have been achieved in combinationwith chemotherapy and/
or after T celledepleted transplantations [12,13]. Because
immunotherapy is usually more effective when the disease is
minimal, early detection of disease relapse improves the
ability to cure patients [14].
The thymus and activation-regulated chemokine (TARC),
also known as chemokine ligand 17, is a small cytokine be-
longing to the CC-motif chemokine family. TARC is expressed
Table 1
Patient Characteristics
Characteristic Value
No. of patients 24
Male/female, n 14/10
Age, median (range), yr 32 (18-59)
Histological subtypes, n
Nodular sclerosis 22
Mixed cellularity 1
Lymphocyte rich 1
Time from diagnosis to alloSCT, median (range), mo 31 (16-208)
No. of previous treatments, median (range) 5 (3-12)
Previous autologous transplantations, n (%) 23 (96)
Disease stage at relapse before alloSCT, n (%)
Stage II 4 (17)
Stage III 7 (29)
Stage IV 13 (54)
Disease status before transplantation, n (%)
CR 10 (42)
Partial remission 9 (37)
PD/SD 5 (21)
Donor type and RIC regimen/GVHD prophylaxis, n (%)
HLA identical sibling
Thiothepa-ﬂudarabine-cyclophosphamide/MTX-CSA 7 (29)
Unrelated 14 (58)
Thiothepa-ﬂudarabine-cyclophosphamide-ATG/
MTX-CSA
6
Thiothepa-cyclophosphamide-ATG/MTX-CSA 8
HLA haploidentical sibling
Thiotepa/ﬂudarabine/cyclophosphamide-TBI
2 Gy-þ/ATG
3 (13)
RIC indicates reduced-intensity conditioning; MTX, methotrexate; CSA,
cyclosporine; ATG, antithymocyte globulin; TBI, total body irradiation.
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derived dendritic cells and by endothelial cells and specif-
ically binds chemokine receptor 4, which is expressed by
regulatory T and T helper 2 cells. A preliminary study already
demonstrated TARC expression in Reed-Sternberg cells by
immunohistochemistry, thus justifying the abundant inﬁltrate
of T helper 2 cell in the HL microenvironment [15]. The
expression of TARC is particular to classic HL, as it is not
expressed in lymphocyte-predominant HL and in B cell non-
Hodgkin lymphomas [16]. About 85% of patients affected by
HL also have elevated TARC levels in the serum at diagnosis
[17,18]. Serum TARC level is correlated with disease stage, B
symptoms, bulky disease and extra-nodal involvement,
erythrocyte sedimentation rate, and leukocyte and lympho-
cyte counts [17,19]. Patients who experienced disease pro-
gression after ﬁrst-line therapy had higher levels of TARC at
baseline and after therapy [17,19]. In fact, a TARC level > 2000
pg/mL after therapy correlated with worse survival and Sauer
et al. showed that patients with a baseline TARC > 10,000
pg/mL had higher risk of not responding to ﬁrst-line chemo-
therapy [17,19]. In addition, recent data have underlined the
correlation between serum TARC levels and tumor burden as
detected by PET [20]. Elevated serum TARC levels have been
detected in few other pathological conditions, such as atopic
diseases and mycosis fungoides [21]. Based on these data,
TARC may be considered a sensitive and quite speciﬁc serum
marker for classical HL, although an agreement on the normal
and predictive cut-off values has not yet been established
[17-19,22].
Our study had the following aims: (1) to assess whether
serum TARC levels correlated with disease status before and
after alloSCT, (2) to correlate TARC levels with PET results
after alloSCT, and (3) to evaluate whether the combined re-
sults of TARC and PET can increase the ability to assess or
predict relapse after alloSCT.
PATIENTS AND METHODS
Patient Characteristics
This was a prospective observational study approved by the institutional
review board. From May 2009 to March 2014, serial plasma samples were
prospectively collected from 24 consecutive patients with HL who under-
went an alloSCT at Fondazione IRCCS Istituto Nazionale dei Tumori. All
participating patients gave their signed informed consent. Four patients
who received an alloSCT during this period were not included in this anal-
ysis: 3 because of nonadherence to the protocol and 1 because of toxic death
before engraftment. Table 1 summarizes patient characteristics. Patients
were heavily pretreated. Twenty-three (96%) previously received an autol-
ogous transplantation. At the time of relapse before alloSCT, disease stage
was distributed as follows: stage IV, n ¼ 13 (54%; bone, n ¼ 7; lung, n ¼ 6;
liver, n¼ 2; soft tissue, n¼ 2); stage III, n¼ 7 (29%); and stage II, n ¼ 4 (17%).
Three patients had B symptoms at pre-alloSCT relapse. Before alloSCT, 10
patients (42%) were in complete remission (CR), 9 (37%) were in partial
remission, and 5 (21%) were in stable or progressive disease (PD/SD).
PET Monitoring
Two-deoxy-2-[ﬂuorine-18] ﬂuoro-D-glucose (FDG) -PET imaging was
performed before alloSCT, around 1 month after alloSCT, every 3 months
during the ﬁrst year of follow-up, and at least every 6 months thereafter.
FDG imagingwas performed 6010minutes after intravenous injection
of FDG (3 to 6 mCi/kg patient’s weight), in patients in fasting status (at least
6 hours) and with blood glucose levels< 140 mg/dL, using dedicated hybrid
PET/computerized tomography (CT) systems (General Electric Discovery LS
or 3D-TOF 64 Philips Gemini, Waukesha, WI). Imaging protocol included CT
scout to deﬁne the body axial extension to be imaged (normally upper thigh
to skull base), low-dose no-contrast CT scan, and PET scan. Using dedicated
workstations (Philips Extended Brilliance Workspace, Eindhoven, The
Netherlands), visual analysis of FDG ﬁndings was performed by 2 experi-
enced nuclear medicine physicians, adopting the criteria suggested by
Juweid et al. [23]. Brieﬂy, an FDG-PET scan was read as positive in presence
of any abnormal focal FDG uptake greater than mediastinal blood uptake,
used as reference of background activity, with a corresponding morphologicalteration in the coregistered CT images. Two radiologists who had experi-
ence in lymphoma patients performed all the PET scans, and they were
blinded to the fact that the patients were enrolled in the TARC study. PET
scans were performed without knowledge of TARC results.
Serum TARC Monitoring
Serum from patients was stored at 80C until processing of samples in
a double-antibody sandwich ELISA, according to the manufacturer’s guide-
lines (R&D Systems, Minneapolis, MN). Serum TARC level was assessed in 40
healthy subjects with a similar age range as our patients and the results
showed amedian TARC of 325 pg/mL (range,184 to 420). These results are in
line with previous published studies and they conﬁrm the reproducibility of
the assay [17-20].
Study samples were analyzed without knowledge of disease status and
treatment results. Serum TARC levels were measured before and after
alloSCT. After alloSCT, TARC was measured at least every 30 days for the ﬁrst
3 months; thereafter, every 2 months during the ﬁrst year and then at the
time of clinical check-up. In total, 222 samples were assessed after alloSCT
with a median of 9 time points for each patient (range, 2 to 19). The median
interval between assessments was 47 days (range, 7 to 700).
We excluded 1 patient (unique patient number [UPN] 4) from the
analysis because he always presented very high TARC values regardless of
disease status; therefore, we considered TARC as a nonrepresentative
marker of disease in this patient.
Statistics
Continuous data differences were performed using t-test. To deﬁne a
cut-off value of TARC with the highest sensitivity and speciﬁcity, we per-
formed a receiver operating characteristics (ROC) curve analysis. Progres-
sion-free survival (PFS), deﬁned as progression of the disease or death
regardless of the cause, was estimated using the Kaplan-Meier method, and
comparison of PFS between groups were performed by the log-rank test.
Statistical analyses and survival curves were performed using Graphpad
PRISM version 5.02.
RESULTS
Pretransplantation TARC
The pretransplantation serum TARC level was available in
all but 1 patient. A pretransplantation PET was available in 14
of 22 evaluable patients. The other 8 patients were assessed
Figure 1. TARC values in PET-positive and PET-negative patients and in patients who relapsed after alloSCT. The line indicates the cut-off value of 1726 ng/mL.
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radiotherapy before alloSCT and the other 4 patients because
the timing of alloSCT precluded the possibility of performing
the exam.
PET-positive patients had a median TARC value of 2542
pg/mL (range, 94 to 13,870), whereas PET-negative patients
had a median TARC value of 721 pg/mL (range, 209 to 1332)
(P¼ .204). Twopatients (UPN13 andUPN18) had inconclusive
PETs, due to a very low FDG uptake (standardized uptake
value [SUV]  2.5) in a previously positive disease site: they
had a pretransplantation serum TARC level of 710 pg/mL and
931 pg/mL, respectively.
Based on the disease status by CT or/and PET scan before
alloSCT of all the evaluable 22 patients, the median serum
TARC level was 684 pg/mL (range, 195 to 2293) in CR pa-
tients, 1528 pg/mL (range, 94 to 13,870) in partial remission
patients, and 2516 pg/mL (range, 1159 to 5053) in PD/SD
patients (P ¼ .108).Figure 2. PFS of the patients who had at least 1 value of TARC > 1726 ng/mL
within the ﬁrst year after alloSCT (dotted line) and those who had always TARC
< 1726 ng/mL during the ﬁrst year after alloSCT (continuous line) (P ¼ .031).Post-transplantation TARC Monitoring
The median follow-up from alloSCT was 30 months
(range, 2 to 54). At the last follow-up, 2 patients died of
disease progression (UPN9 and UPN14), and 2 patients died
of nonrelapse mortality (UPN6 of acute graft-versus-host
disease [GVHD] and UPN21 of infection).
Two patients (UPN9 and UPN14) with persistent disease
after alloSCT had a median serum TARC level of 22,397
pg/mL (range, 602 to 106,578), whereas 13 patients who
were in persistent CR after alloSCT had a median TARC of
620 pg/mL (range, 12 to 4333) (P < .0001). We excluded
UPN6 because disease status was not determined at the last
follow-up. Seven patients achieved PET negativity but they
eventually relapsed. Their outcome has been described in
detail below.Figure 1 shows TARC values in PET-negative and PET-
positive patients and in those who relapsed after alloSCT.
TARC Cut-off Value
To assess a cut-off value of TARC correlated to PET posi-
tivity, we selected only the TARC values performed on the
days of PET scans (n ¼ 66). We observed a signiﬁcant dif-
ference between TARC levels correlating to a positive or a
negative PET (P < .0001). Based on these data, the ROC curve
showed that the cut-off value of 1726 pg/mL had a sensitivity
and speciﬁcity of 100% and 71%, respectively.
Patients with at least 1 TARC > 1726 ng/mL during the
ﬁrst year after alloSCT had a 1-year PFS of 47% versus 78% of
those with TARC < 1726 ng/mL (P ¼ .031) (Figure 2).
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ng/mL) was 67% versus 53% (P ¼ .77).
TARC and Relapse after alloSCT
Seven patients achieved CR after alloSCT, but they even-
tually relapsed after a median of 13 months (range, 6 to 25)
after alloSCT. UPN1 underwent transplantation in PD with a
pretransplantation TARC of 2609 pg/mL. Only 2 TARC values
were available before relapse, showing a very high level 4
months before PET positivity (4108 pg/mL) and at time of
relapse (3614 pg/mL). UPN2 achieved CR after alloSCT, but 9
months later, TARC started increasing above 2000 ng/mL
until the end of the ﬁrst year, when the TARC value reached
3506 pg/mL and the PET turned positive in a previous disease
site at the mediastinum. In UPN11, TARC started increasing 5
months after alloSCT with values below 1000 ng/mL, but at
that time the PET was inconclusive. He relapsed after 10
months with a TARC value of 1553 pg/mL and a positive PET
at previously involved abdominal lymph nodes. UPN13
achieved PET negativity on day 30, when TARC dropped
down to 361 pg/mL. From the second month, TARC increased
progressively, but a CT scan on day 120 showed lymph nodes
with a stable size compared with the CT scan performed
before alloSCT. Six months after alloSCT, TARC was 1351
pg/mL and the PET scan showed a signiﬁcant uptake in those
abdominal lymph nodes. UPN15 achieved a metabolic CR on
day 30 and TARC remained low during the next 15 months;
then, it increased progressively achieving a value of 1558
pg/mL in the 19th month, when PET became positive as well.
Similarly, UPN17 achieved PET negativity on day 60 with a
TARC value of 403 pg/mL. Successively, TARC increased pro-
gressively achieving 1007 pg/mL on day 314 when the PET
became positive at the lumbar spine, a previous disease site.
UPN16 relapsed after 2 years: TARC value was above the
cut-off of 1726 ng/mL since 1 year after alloSCT. In these 7
patients, TARC was increasing before the PET scan became
positive.
Because we observed an interpatient variability of TARC
values at the time of relapse detected by PET, with 4 patients
relapsing when TARC was less than 1726 ng/mL, we hy-
pothesized that the relative increase, rather than the abso-
lute value of TARC, was suggestive of metabolic relapse. To
answer this question, we compared the day-30 TARC results
(when all patients had a negative PET) to the TARC value at
the time of PET positivity and we observed that the median
fold increase was 3.19 (range, 1.66 to 7.11). The fold increase
was signiﬁcantly higher compared with the fold increase of
TARC of the patients who were always in CR, in which the
day-30 TARC was compared with the TARC value at 1 year
(P ¼ .038).
Figure 3 shows the TARC monitoring in 6 patients who
relapsed after alloSCT and therapy of relapse.
TARC and GVHD
Six patients (26%) experienced acute GVHD (grade 1, n ¼
3; grade 2, n ¼ 2; grade 3, n ¼ 1). Nine patients (39%)
experienced chronic GVHD (limited, n ¼ 5; extensive, n ¼ 4).
UPN6 died of GVHD and UPN11 was still on low-dose
cyclosporine therapy at the time of last follow-up because
of ocular GVHD. The remaining patients experienced only
transient GVHD episodes and showed no sign of active GVHD
at the last follow-up.
Overall, only 7 of 222 (3%) serum TARC measures
increased due to acute or chronic GVHD, whereas only 6 of
them were above the cut-off of 1726 ng/mL (2.7%). UPN6developed grade 2 acute GVHD on day 46 after alloSCT and
on day 60 TARC was 4388 ng/mL, which decreased to 562 ng/
mL on the next time point, when PET conﬁrmed CR. UPN11
developed grade 2 acute GVHD on day 40 when TARC was
1734 ng/mL, but TARC decreased to 59 ng/mL 90 days later,
remaining low until disease progression. UPN20 had grade 3
acute GVHD on day 30 and a serum TARC level of 4333 ng/mL
that decreased to 49 pg/mL on day 60, remaining low until
the last follow-up at 1 year. UPN19 had 2 elevated serum
TARC levels: 1 on day 30 (2981 ng/mL) after a T cellereplete
haploidentical transplantation and another on day 180 (3338
ng/mL) at the onset of eczematoid chronic GVHD. All the
remaining 10 measures for this patient showed low TARC
levels correlating with CR status at 15 months after alloSCT.
Similarly, UPN16 had a TARC value of 2689 ng/mL on day 243
and UPN23 had a TARC value of 1690 ng/mL on day 75, when
they developed a transient eczematoid form of skin GVHD.
In all of these cases, TARC was high at the time of GVHD
onset and decreased rapidly over time. The pattern of in-
crease was signiﬁcantly different compared with the pattern
correlated to disease relapse when TARC was persistently
and/or progressively higher.
DISCUSSION
HL that relapses after an alloSCT represents an unresolved
issue, as the disease is considered incurable. Recently, the
results achieved with the use of new drugs, such as bren-
tuximab, are encouraging, although they still have to
demonstrate their potential in the long term [24,25]. The use
of donor lymphocyte infusions alone or in combination with
radio-chemotherapy or new drugs may represent an option
after alloSCT, but it remains essential to detect relapse early
because the graft-versus-tumor effect works when the dis-
ease is limited [14]. Unlike other hematological malignancies,
in which speciﬁc tumor markers are available for minimal
residual disease monitoring, PET still represents the best
exam to detect disease recurrence in HL patients. Previous
studies have demonstrated a sensitivity of 84% and a speci-
ﬁcity of 90% for the detection of residual disease by PET in HL
patients [26]. Despite these results, there are some open
questions regarding reproducibility, mainly related to the
fact that PET results are based on a visual assessment [27,28].
In our study, to increase the reproducibility of the PET results
and to avoid biases, 2 experienced radiologists performed all
the PET scans in HL patients and were blinded to the fact that
some of them were enrolled in the TARC study. In addition,
emerging data suggest that a signiﬁcant portion of patients
may have inconclusive or false-positive PET results, espe-
cially in some clinical conditions (eg, patients with concur-
rent inﬂammation or infection). In these cases, a disease
biopsy or a second exam are recommended [29]. For all of
these reasons, and taking into account that PET is a very
expensive exam and exposes patients to radioactivity, the
identiﬁcation of a tumor marker of disease relapse would be
useful.
The correlation between serum TARC with tumor burden
and response after chemotherapy has already been shown. In
particular, 2 recent papers correlated TARC values with PET
results before and after ﬁrst-line chemotherapy but, to the
best of our knowledge, no data are available in the setting of
alloSCT and with a longitudinal observation [19,20]. An
additional marker to detect relapse, other than PET, is
potentially more useful after alloSCT compared with ﬁrst and
second-line therapies for 2 main reasons: (1) the very high
risk of relapse of allografted patients; and (2) the clinical
Figure 3. TARC monitoring in patients who relapsed after allogeneic stem cell transplantation. CSA indicates cyclosporine; VGPR, very good partial remission;
PR, partial remission; benda, bendamustine; chemo, chemotherapy.
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adoptive immune therapy. As a consequence of the very
small percentage of HL patients who unfortunately need an
alloSCT, the number of our patients is limited compared with
other studies. Nevertheless, monitoring of TARC during a
median follow-up of 30 months was able to provide inter-
esting results.
Pre-alloSCT serum TARC levels were higher in patients
with active disease at the time of transplantation compared
with those in CR, although the results were not signiﬁcantly
different, probably because of the limited number of pa-
tients. By monitoring TARC after alloSCT, we showed that
those patients who were always PET-positive had signiﬁ-
cantly higher serum levels compared with those who were
always PET-negative. In patients who achieved CR after
alloSCT but eventually relapsed, TARC dropped down at the
time of CR but then progressively increased before the PET
became positive. These data suggest that TARC, which
increases when the disease is still minimal and undetectable
by PET, may be a very sensitive and early serum HL marker
of relapse. In this regard, there are 2 limits of our study:
(1) because this study started in 2009, PET results were basedon Juweid criteria and not on Deauville criteria, which have
been ﬁrst validated to assess interim PET in HL patients un-
dergoing ﬁrst-line therapy [23,27]; and (2) we did not
perform biopsies to conﬁrm disease recurrence; however, all
patients who relapsed after alloSCT were PET-positive in
sites that were previously involved by lymphoma and were
not easy to biopsy. We performed a ROC curve analysis by
selecting those TARC values obtained at the time of PET,
showing that the cut-off of 1726 pg/mL was highly sensitive
and quite speciﬁc for metabolic relapse. In particular, pa-
tients who had at least 1 TARC value above 1726 ng/mL
during the ﬁrst year after alloSCT had a signiﬁcantly worse
PFS compared with those who always had a TARC less than
1726 ng/ml at 1 year after transplantation.
We identiﬁed 3 main limitations of TARC monitoring.
First, TARC is not always informative, as in 1 patient TARC
was always high, regardless of disease status and without
any known reason. Other authors reported that TARCwas not
representative of disease status in about 15% of HL patients
[17,18]. Thus, it is advisable to have a baseline serum TARC
measure taken at diagnosis and/or at the time of high disease
burden and after chemotherapy to select those patients
Figure 4. Potential use of TARC monitoring in patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
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TARC monitoring is related to the increase at the time of
relapse. Wewere able to deﬁne a cut-off value of 1726 ng/mL
correlating with PET positivity and this result is in line with
previous published data that identiﬁed patients with TARC
> 2000 pg/mL as those with a decreased survival after
chemotherapy [17]. Nevertheless, 4 patients relapsed with a
TARC value < 2000 ng/mL. Our analysis showed that the fold
increase of TARC rather than the absolute value can be sug-
gestive of relapse, underlying the importance of a sequential
monitoring. A third limit of TARC monitoring is unique to the
allotransplantation setting: despite the limited number of
patients, we observed high serum TARC levels in some
patients with GVHD, suggesting that the speciﬁcity of the
marker may be low in this condition. Again, in these cases
the sequential monitoring was useful as it showed a rapid
decrease of TARC after initiation of therapy and/or the res-
olution of GVHD, instead of a progressive increase in those
patients who relapsed. The increase of TARC with the onset
of GVHDmay be explained by previous studies carried out in
atopic diseases, demonstrating the expression of TARC in the
activated endothelium of inﬂamed skin and the stimulation
of TARC production by several cytokines, such as tumor ne-
crosis factor-a, which is also involved in the pathogenesis of
the GVHD [30,31]. Notably, the small number of elevated
TARC measures that was attributed to GVHD were observed
in patients affected by either  2 grade acute GVHD or
eczematoid chronic GVHD [32,33].
Taking into account these limitations, we believe that
serum TARC monitoring may represent an helpful, fast,
noninvasive, and low-cost tool that can be included in the
post-transplantation follow-up of HL patients, together with
PET, to detect disease relapse (Figure 4). Whether or not a
biopsy conﬁrmation of a PET positivity is mandatory in this
setting remains open and larger prospective clinical trials are
needed to address this issue and to validate our results.
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